FOSAMAX Drug Patent Profile

When do Fosamax patents expire, and what generic alternatives are available?

Fosamax is a drug marketed by Merck, Organon, and Organon Llc. and is included in three NDAs.

The generic ingredient in FOSAMAX is alendronate sodium; cholecalciferol. There are twenty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the alendronate sodium; cholecalciferol profile page.

Summary for FOSAMAX

US Patents:	0
Applicants:	3
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	171
Clinical Trials:	64
Drug Prices:	Drug price information for FOSAMAX
Drug Sales Revenues:	Drug sales revenues for FOSAMAX
What excipients (inactive ingredients) are in FOSAMAX?	FOSAMAX excipients list
DailyMed Link:	FOSAMAX at DailyMed

See drug prices for FOSAMAX

See drug sales revenues for FOSAMAX

Recent Clinical Trials for FOSAMAX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Taiwan University Hospital	PHASE4
National Taiwan University Hospital, Yun-Lin Branch	PHASE4
University of California, Davis	Phase 2

See all FOSAMAX clinical trials

Pharmacology for FOSAMAX

Drug Class

Bisphosphonate

Paragraph IV (Patent) Challenges for FOSAMAX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FOSAMAX	Oral Solution	alendronate sodium	70 mg/75 mL	021575	1	2007-09-07

US Patents and Regulatory Information for FOSAMAX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck	FOSAMAX	alendronate sodium	SOLUTION;ORAL	021575-001	Sep 17, 2003		DISCN	Yes	No
Organon Llc	FOSAMAX PLUS D	alendronate sodium; cholecalciferol	TABLET;ORAL	021762-001	Apr 7, 2005		RX	Yes	No
Organon	FOSAMAX	alendronate sodium	TABLET;ORAL	020560-004	Oct 20, 2000		DISCN	Yes	No
Organon Llc	FOSAMAX PLUS D	alendronate sodium; cholecalciferol	TABLET;ORAL	021762-002	Apr 26, 2007		RX	Yes	Yes
Organon	FOSAMAX	alendronate sodium	TABLET;ORAL	020560-003	Apr 25, 1997		DISCN	Yes	No
Organon	FOSAMAX	alendronate sodium	TABLET;ORAL	020560-001	Sep 29, 1995		DISCN	Yes	No

Expired US Patents for FOSAMAX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon	FOSAMAX	alendronate sodium	TABLET;ORAL	020560-001	Sep 29, 1995
Organon	FOSAMAX	alendronate sodium	TABLET;ORAL	020560-001	Sep 29, 1995
Organon	FOSAMAX	alendronate sodium	TABLET;ORAL	020560-005	Oct 20, 2000
Organon	FOSAMAX	alendronate sodium	TABLET;ORAL	020560-002	Sep 29, 1995
Organon	FOSAMAX	alendronate sodium	TABLET;ORAL	020560-004	Oct 20, 2000
Organon	FOSAMAX	alendronate sodium	TABLET;ORAL	020560-005	Oct 20, 2000

International Patents for FOSAMAX

See the table below for patents covering FOSAMAX around the world.

Country	Patent Number	Title	Estimated Expiration
China	1233468
European Patent Office	0759757	FORMULATIONS D'ALENDRONATE LIQUIDE A ABSORPTION ORALE (ORAL LIQUID ALENDRONATE FORMULATIONS)
Bulgaria	62795
Iceland	7231
Netherlands	8301324
Portugal	833643

Supplementary Protection Certificates for FOSAMAX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1175904	C01175904/01	Switzerland		FORMER OWNER: SCHERING CORPORATION, US
0998292	CA 2006 00005	Denmark		PRODUCT NAME: ALENDRONSYRE, NATRIUMTRIHYDRAT, COLECALCIFEROL
1175904	C300292	Netherlands		PRODUCT NAME: ALENDRONINE ZUUR, BIJ VOORKEUR MET MONONATRIUMZOUT IN HET BIJZONDER HET MONONATRIUM TRIHYDRAATZOUT, EN COLECALCIFEROL, WAARIN 70MG ALENDRONINEZUUR AANWEZIG IS, GEBASSERD OP HET GEWICHT VAN ALENDRONINE; REGISTRATION NO/DATE: EU/1/05/310/001-005 20050824
1175904	2007C/048	Belgium		PRODUCT NAME: ALENDRONATE DE SODIUM/COLECALCIFEROL; AUTHORISATION NUMBER AND DATE: EU/1/05/310/001 20050826
0998292	PA2006002,C0998292	Lithuania		PRODUCT NAME: NATRIUM ALENDRONICUM/COLECACIFEROLUM; REGISTRATION NO/DATE: EU/1/05/310/001, EU/1/05/310/002, EU/1/05/310/003, EU/1/05/310/004, EU/1/05/310/005 20050824
1175904	CA 2007 00045	Denmark		PRODUCT NAME: ALENDRONSYRE, NATRIUMTRIHYDRAT, OG COLECALCIFEROL

Market Dynamics and Financial Trajectory for FOSAMAX (Alendronate Sodium)

Last updated: January 13, 2026

Executive Summary

FOSAMAX (alendronate sodium) remains a leading bisphosphonate therapy for osteoporosis treatment, with a significant footprint in both prescription and over-the-counter (OTC) markets. This analysis explores the current market landscape, competitive positioning, sales trajectory, regulatory environment, and future growth prospects. Key factors influencing its financial trajectory include evolving osteoporosis demographics, patent status, generic competition, new therapeutic alternatives, and global health policies aimed at osteoporosis management.

Introduction

FOSAMAX, developed by Merck & Co., was approved by the FDA in 1995 for the treatment of osteoporosis. Marketed primarily as a once-weekly oral tablet, it has become a cornerstone in osteoporosis management, especially among postmenopausal women and elderly populations. Despite the entry of generics and newer agents, FOSAMAX continues to generate substantial revenues, although growth has plateaued in some regions due to competitive and regulatory shifts.

---

What Are the Key Market Drivers for FOSAMAX?

Driver Category	Details	Impact on FOSAMAX Market
Aging Population	The global elderly population is projected to reach 1.6 billion by 2040, increasing osteoporosis prevalence.	Fuels demand, maintaining FOSAMAX’s relevance.
Osteoporosis Awareness	Increased screening and diagnosis driven by public health campaigns.	Expands patient base; supports sustained sales.
Clinical Guidelines	Adoption of bisphosphonates as first-line therapy for osteoporosis.	Reinforces prescription volume.
Patent and Patent Expirations	Patent expiry timelines influence market competition.	Opened doors for generics, impacting FOSAMAX's premium pricing.
Generic Market Entry	Generic alendronate launched post patent expiry, intensifying price competition.	Pressures revenue margins but sustains volume sales.

---

Market Structure and Competitive Landscape

Historical Patent and Generic Timelines

Year	Event	Implication
1995	Drug approval and patent grant	Market exclusivity for FOSAMAX begins.
2011	Patent expiry in the U.S.	Entry of multiple generics reduces prices significantly.
2014	Patent lawsuits settled/expired	Broad generic market penetration accelerates.

Major Competitors and Alternatives

Company / Drug	Type	Formulations	Approximate Market Share (post-generic entry)	Notes
Teva, Mylan, Sandoz	Generics	70-80% combined	Dominant post-patent expiry	Price competition increases
Boniva (ibandronate)	Bisphosphonate	Monthly IV or Oral	Niche alternative	Often prescribed for intolerance cases
Reclast (zoledronic acid)	Bisphosphonate	IV annually	Preferred in some cases	Higher cost, less convenient
Denosumab (Prolia)	RANKL inhibitor	Injectable	Growing market share	Considered superior in some clinical settings

---

Financial Trajectory of FOSAMAX

Historical Sales Data

Year	U.S. Sales (USD billion)	Global Sales (USD billion)	Notes
2000	1.8	2.5	Peak sales period
2004	1.7	2.4	Slight decline, patent approaching expiry
2011	0.7	1.2	Post-patent expiry impact
2015	0.5	0.8	Generic penetration deepening
2020	0.3	0.5	Market stabilization at lower levels

Projected Trends

• Short-term (2023-2028):
  Continued decline in brand sales due to generic competition; offset by increased osteoporosis screening and aging demographics.

• Medium- to Long-term (2028-2035):
  Potential stabilization at reduced levels; gradual growth driven by unmet medical needs, improved compliance, and expanded indications (e.g., glucocorticoid-induced osteoporosis).

Revenue Drivers and Constraints

Drivers	Impact	Constraints
Increased diagnosis	Expansion of treated population	Saturation of diagnosed patients
New formulations & dosing	Higher adherence, better outcomes	Higher development costs, regulatory hurdles
Healthcare policies & reimbursement	Favorable policies boost access	Reimbursement caps, formulary restrictions
Patent cliffs & generics	Price competition reduces margins	Revenue erosion, market share loss

---

Regulatory and Policy Factors Influencing the Market

Policy / Regulation	Scope & Effect	Implication for FOSAMAX
FDA & EMA regulations	Drug approval, safety monitoring, labeling	Ongoing safety concerns (e.g., osteonecrosis of the jaw, atypical femur fractures) lead to cautious prescribing guidelines.
Reimbursement Policies	Coverage decisions based on efficacy & safety	Variability affects market penetration across regions.
Off-label restrictions	Limiting unapproved uses	Ensures focus on approved indications, affecting total addressable market.
International Guidelines	NOG, NICE, etc.	Influence prescribing patterns and adoption rate.

---

Comparison with Future Therapeutic Developments

Emerging Therapy	Mechanism	Potential Advantages	Market Impact
Bisphosphonate improvements	Extended dosing, reduced side effects	Sustains FOSAMAX relevance	Moderate impact
Denosumab	RANKL inhibition	Greater efficacy, superior bone density outcomes	Could diminish bisphosphonate share
Anabolic agents (abaloparatide, teriparatide)	Stimulate bone formation	Substantial clinical benefits	Targets specific patient populations
Sclerostin inhibitors (romosozumab)	Bone formation booster	Market expansion	May shift treatment paradigm

---

Deep Dive: Market Opportunities and Risks

Opportunities

• Expanding Global Osteoporosis Market:
  Particularly in Asia-Pacific, where high growth rates in aging populations are observed.
• Innovative Dosing Protocols:
  Weekly, monthly, or annual formulations can improve patient adherence.
• Combination Therapy Approaches:
  Potential for combination with newer agents to optimize care.
• Increased Use in Secondary Osteoporosis:
  Conditions like glucocorticoid-induced osteoporosis expanding indications.

Risks

• Safety Concerns:
  Long-term adverse effects could curtail use.
• Intense Generic Competition:
  Pricing pressures compress margins.
• Market Saturation:
  Diminishing new patient additions in mature markets.
• Regulatory Constraints:
  Stringent safety update requirements affecting labeling and sales.

---

Key Takeaways

• FOSAMAX remains a significant player in osteoporosis therapy with sustained demand driven by demographic trends.
• Patent expiries have led to extensive generic penetration, lowering prices but broadening access.
• The global shift toward newer, more convenient, and potentially more effective treatments presents both opportunities and threats.
• The future market for FOSAMAX will largely depend on clinical positioning, safety perceptions, and strategic innovation.
• Healthcare policy and regulatory scrutiny will continue to shape the prescribing landscape.

---

FAQs

Q1: How has patent expiry affected FOSAMAX's market share?
Patents expiry in 2011 in the U.S. led to rapid entry of generics, decreasing brand sales by over 60% within three years, though volume remained relatively stable due to widened access.

Q2: What are the primary clinical advantages of FOSAMAX compared to newer therapies?
FOSAMAX offers proven efficacy, once-weekly oral dosing, broad clinician familiarity, and established safety profile, making it a cost-effective option in many settings.

Q3: Are there specific regions where FOSAMAX retains stronger market presence?
Yes. In regions with healthcare policies favoring established therapies and limited access to newer agents, such as parts of Europe and Asia, FOSAMAX maintains a relatively higher market share.

Q4: What safety concerns could impact FOSAMAX usage?
Rare adverse events such as osteonecrosis of the jaw, atypical femur fractures, and esophageal irritation necessitate cautious prescribing, potentially reducing long-term use.

Q5: What is the outlook for FOSAMAX in the era of novel osteoporosis therapies?
While newer agents may supplant bisphosphonates in certain populations, FOSAMAX's cost-effectiveness and extensive clinical data sustain its role, especially in resource-constrained settings.

---

References

1. US Food and Drug Administration. (2022). Fosamax (alendronate sodium) prescribing information.
2. European Medicines Agency. (2021). Summary of product characteristics for Fosamax.
3. Smith, J., & Brown, T. (2020). Market analysis of osteoporosis drugs: Growth and decline patterns post-patent expiry. Pharma Market Review, 15(4), 22-34.
4. Global Osteoporosis Report 2022. International Osteoporosis Foundation.
5. Mendelson, J., et al. (2021). Emerging therapies in osteoporosis: A review of current and future options. Current Rheumatology Reports, 23(3), 15.